Stoke Therapeutics (STOK) Research & Development (2018 - 2026)

Stoke Therapeutics' Research & Development history runs 9 years deep, the most recent figure standing at $39.7 million for Q1 2026.

• In Q1 2026, Research & Development rose 21.41% year-over-year to $39.7 million; the TTM figure through Mar 2026 stood at $144.9 million (up 45.74% YoY), while the FY2025 annual figure was $137.9 million, up 54.74% from the prior year.
• Research & Development was $39.7 million for Q1 2026 at Stoke Therapeutics, down from $41.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $41.7 million in Q4 2025 to a low of $18.3 million in Q1 2022.
• Historically, Research & Development has averaged $25.1 million across 5 years, with a median of $21.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Research & Development soared 84.7% in 2022, then gained 0.81% in 2023.
• A 5-year view of Research & Development shows it stood at $21.1 million in 2022, then grew by 3.41% to $21.8 million in 2023, then gained by 7.55% to $23.4 million in 2024, then jumped by 78.01% to $41.7 million in 2025, then retreated by 4.85% to $39.7 million in 2026.
• The last three Research & Development figures came in at $39.7 million (Q1 2026), $41.7 million (Q4 2025), and $37.7 million (Q3 2025), per Business Quant data.